Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …

Abstract In eukaryotes, ubiquitin (Ub)-dependent proteolysis is essential for bulk protein
turnover as well as diverse processes including cell-cycle control, differentiation, antigen …

Ubiquitination is initiated by transfer of ubiquitin (Ub) from a ubiquitin-activating enzyme (E1)
to a ubiquitin-conjugating enzyme (E2), producing a covalently linked intermediate (E2–Ub) …

Targeted protein degradation is a promising therapeutic strategy capable of overcoming the
limitations of traditional occupancy-based inhibitors. By ablating all of the associated …

The ubiquitin-proteasome pathway (UPP) is the main route of protein degradation in
eukaryotic cells and is a common mechanism through which numerous cellular pathways …

Efficacy and selectivity of molecules inducing protein degradation depend on their affinity to
the target protein but also on the type of E3 ubiquitin ligase that is recruited to trigger …

Depletion of specific cellular proteins is a powerful tool in biological research and has many
medical and agricultural benefits. In contrast to genetic methods currently available to …

Protein ubiquitination is a multi-functional post-translational modification that affects all
cellular processes. Its versatility arises from architecturally complex polyubiquitin chains, in …

Targeted protein degradation (TPD) is a promising strategy to remove deleterious proteins
for therapeutic benefit and to probe biological pathways. The past two decades have …

Ubiquitin-like proteins (UBLs) are conjugated by dynamic E1–E2–E3 enzyme cascades. E1
enzymes activate UBLs by catalysing UBL carboxy-terminal adenylation, forming a covalent …